Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Submission of 13-week Phase IIa Study Protocol to FDA ...Middle East

- ASC30 oral once-daily tablet demonstrated a 6.5% placebo-adjusted mean body weight reduction from baseline after four-week treatment using weekly doses with titrations of 2 mg, 10 mg, 20 mg, and 40 mg doses. - ASC30 oral once-daily tablet also demonstrated a 4.5% placebo-adjusted mean...

Hence then, the article about ascletis announces positive topline results of u s phase ib multiple ascending dose study of small molecule oral glp 1r agonist asc30 and submission of 13 week phase iia study protocol to fda was published today ( Wednesday 23/04/2025 - 02:48 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Submission of 13-week Phase IIa Study Protocol to FDA )

Also on site :

• The year data centers went from backend to center stage
• Driver dies in fiery freeway crash on Christmas Eve near Sacramento
• 2 people hurt in plane crash into North Sacramento field